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Summary
Aim. the main objective of the presented study was to investigate relationships between lifetime comor-
bidity in bipolar disorder to demographic and clinical variables and level of functioning in current remission. 
the prevalence of comorbidity and gender and bipolar subtype differences were also assessed. 
Subjects and methods. Seventy three bipolar I or II outpatients in remission (Hamilton Depression rat-
ing Scale < 9, Young Mania rating Scale < 7) were assessed by means of the Composite International 
Diagnostic Interview (CIDI) in order to detect possible anxiety and substance use comorbid diagnoses. 
the sample was split according to the presence of different classes of comorbid disorders and the groups 
were compared. 
results. Lifetime psychiatric comorbidity (anxiety and substance use disorders) was 71.2%. the only 
significant differences between sexes were found in general substance use disorders, alcohol and nico-
tine use disorder comorbidities. Only panic disorder with or without agoraphobia and nicotine use disor-
ders were significantly more prevalent in bp I than in bp II.  Significant differences between non-comor-
bid group and comorbid groups were found in some investigated variables. 
Conclusions. Lifetime psychiatric comorbidity is a common phenomenon in bipolar disorder associated 
with some demographic and clinical variables. 
bipolar disorder / anxiety disorders / substance use disorders / comorbidity
INTrOdUCTION
Comorbidity has been defined as the presence 
of more than one specific disorder in a person in 
a defined period of time. This definition extends 
the perspective of comorbidity to a lifetime per-
spective and is the most commonly used in re-
search [1].
The data from both epidemiological and clin-
ical studies indicate that comorbidity is a com-
mon phenomenon among bipolar patients with 
a possible negative impact on clinical character-
istics of bipolar disorder (BP). The rates of co-
morbidity reported by various authors have 
been as diverse as ranging from 31 to 68% [2, 3, 
4, 5], though in the National Comorbidity Sur-
vey (NCS) all the individuals diagnosed as hav-
ing bipolar I disorder suffered from at least one 
psychiatric disorder in their lifetimes [6]. The re-
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ported differences might possibly be explained 
by differences in the characteristics of groups of 
patients studied: bipolar subtype (I, II, or both), 
current psychopathological status (inpatient, 
outpatient, or both; in an acute phase, in remis-
sion, or both), population (clinical, general), or 
in variety of diagnostic instruments and diag-
nostic criteria employed.
Other aspects of comorbidity, i.e. gender and 
subtype differences, have been less extensively 
investigated and require further research due to 
inconsistent and insufficient data.
Comorbidity has also been described in terms 
of its relationships to less favourable clinical 
characteristics of BP and various other variables 
characterizing patients [2, 4, 5, 7].
Relative lack of cross-cultural data on comor-
bidity in bipolar disorder justifies undertaking 
this issue in our preliminary study.
SUBJECTS ANd METHOdS
Seventy three bipolar outpatients who ful-
filled the inclusion criteria were recruited from 
a group of eighty consecutive bipolar patients 
who visited three outpatient psychiatric settings 
in Krakow. The inclusion criteria were: 1) DSM-
IV diagnosis of BP I or BP II; 2) remission con-
firmed by the Hamilton Depression Rating Scale 
(HDRS) scores less than 9 and Young Mania Rat-
ing Scale (YMRS) scores less than 7; 3) age at 
least 18 years; and 4) written informed consent 
obtained before participation in the study. The 
only exclusion criteria were: 1) prominent intel-
lectual or cognitive difficulties that hindered the 
participation in the study; and 2) withdrawal of 
the consent in the course of the study. Seven out 
of eighty consecutive patients did not meet the 
full criteria of remission and were not included 
in the study. All of the included 73 patients com-
pleted the study.
The diagnosis of DSM-IV BP I or BP II were 
confirmed using sections E and F of the Polish 
translation of the Munich Version of the Com-
posite International Diagnostic Interview for 
lifetime assessment (M-CIDI-LT). Lifetime anx-
iety and substance use disorders comorbidities 
were diagnosed using sections D, I, K, L, N of 
the M-CIDI-LT. The computerized version of 
M-CIDI-LT was used. All the assessments with 
M-CIDI-LT were performed by the first author, 
who had been trained in the use of CIDI in a 
WHO-approved training centre in Wroclaw [8, 
9, 10]. The choice of CIDI was dictated by lack of 
the other structured diagnostic instruments (i.e. 
SCID for DSM-IV), which have not been trans-
lated into Polish.
Demographic, clinical and the other selected 
variables were obtained from an interview con-
ducted using a self-constructed semi–structured 
questionnaire. Whenever needed, the missing 
data were completed with information obtained 
from outpatient and inpatient medical records 
and treating psychiatrists.
In the total of 73 patients enrolled in the study, 
five groups were distinguished to perform com-
parisons: BP patients without comorbidity (group 
1), BP patients with any kind of comorbidity (anx-
iety or substance use disorders) (group 2), BP pa-
tients with comorbid anxiety disorders (group 3), 
BP patients with comorbid substance use disor-
ders (group 4), and BP patients with comorbid 
anxiety and substance use disorders (group 5). 
The whole group was also split and compared ac-
cording to gender and bipolar subtype.
Group 1 consisted of twenty one patients 
(28.8%), group 2 of fifty two patients (71.2%), 
group 3 of twenty five patients (34.2%), group 4 
of six patients (8.2%), and group 5 of twenty one 
patients (28.8%).
Statistics
The χ2 test with Yates’ correction or Fisher’s 
exact test were used to analyze categorical vari-
ables. Kruskall-Wallis’ H-tests and one-way anal-
ysis of variance (ANOVA) were performed for 
continuous variables when comparing many 
groups. Student’s t-tests and Mann-Whitney’s 
U-tests were then performed for direct compar-
isons between groups. All statistics were two-
tailed, and significance was set at p< 0.05.
rESULTS
Seventy three bipolar patients completed 
the study. Fifty (68.5%) fulfilled the diagno-
sis of DSM-IV BP I. Thirty one (42.5%) were 
men; the mean age was 44.6 years (SD=11.0, 
range=21.0-67.0).
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Table 1. Lifetime prevalence of comorbid disorders in the 
whole group of bp patients.
Ago = agoraphobia, OCD=obsessive-compulsive disorder, 
ptSD = post traumatic stress disorder
Table 2. Lifetime prevalence of comorbid disorders in bp men and bp woman and bp I and bp II – comparisons.
Comorbid diagnosis
All patients with bipolar  
diagnosis
          n                   %
All disorders (without  
nicotine use disorders) 52 71.2
Anxiety disorders 46 63.0
pD ± Ago 13 17.8
GAD 23 31.5
SAD 14 19.2
Sp 20 27.4
Ago 7 9.6
OCD 3 4.1
ptSD 3 4.1
Substance use disorders  
(without nicotine) 27 37.0
Alcohol 22 30.1
Sedatives and hypnotics 10 13.7
Drugs 2 2.8
Nicotine 43 58.9
Substance use disorders 
(with nicotine) 49 67.1
Table 1 shows comorbidities in all BP-I and 
BP-II cases. Lifetime psychiatric comorbidity 
(with the exclusion of nicotine use disorders) 
was 71.2%. The comorbid lifetime anxiety dis-
orders were found in 63% of the sample, and 
substance use disorders in 37%. After inclusion 
of nicotine use disorders the SUDs comorbidity 
reached 67.1%.
The most prevalent anxiety disorders were 
generalized anxiety disorder (GAD) (23 pa-
tients, 31.5%), simple phobias (SP) (20 patients, 
27.4%), social anxiety disorder (SAD) (14 pa-
tients, 19.2%), and panic disorder with or with-
out agoraphobia (PD±Ago) (13 patients, 17.8%). 
The most prevalent SUDs were alcohol use dis-
orders (22 patients, 30.1%) and nicotine use dis-
orders (43 patients, 58.9%).
Table 2 shows comparisons of comorbidities 
between sexes and BP subtypes. Although the 
rate of comorbidity was higher in men (80.6%) 
than in women (64.3%), it did not reach statisti-
cal significance. The only significant differences 
between sexes were found in general SUDs co-
morbidity (58.1% in men vs. 21.4% in women), 
alcohol use disorders (54.8% in men vs. 11.9% 
in women) and nicotine use disorders (74.2% in 
men vs. 47.6% in women).
There were no statistical differences in comor-
bidity between BP I and BP II. Only PD±Ago 
(24% vs. 4.3%) and nicotine use disorders (72% 
COMOrbID DIAGNOSIS MEN (N=31)
n               %
WOMAN (N=42)
n               %
(χ2) p bp I (N=50)
n               %
bp II (N=23)
     n                 %
(χ2) p
All disorders (without 
nicotine use disorders)
25 80.6 27 64.3 NS 37 74.0 15 65.2 NS
Anxiety disorders 20 64.5 26 62.0 NS 31 62.0 15 65.2 NS
pD ± Ago 6 19.3 7 16.7 NS 12 24.0 1 4.3 <0.05
GAD 12 38.7 11 26.2 NS 17 34.0 6 26.1 NS
SAD 8 25.8 6 14.3 NS 8 16.0 6 26.1 NS
Sp 8 25.8 12 28.6 NS 12 24.0 8 34.8 NS
Ago 3 9.7 4 9.5 NS 3 6.0 4 17.4 NS
OCD 1 3.2 2 4.8 NS 1 2.0 2 8.7 NS
ptSD 0 0 3 7.1 NS 3 6.0 0 0.0 NS
continuation of the table on the next page
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vs. 30.4%) were significantly more prevalent in 
BP I than in BP II.
The direct comparison of the group without 
comorbid disorders (group 1) with the group 
with any comorbid disorder (group 2) revealed 
no significant differences in most investigated 
variables. Bipolar patients with any kind of co-
morbidity were employed significantly less often 
and more frequently were dependant on disabil-
ity pension uptake. Nineteen of them (36.5%), 
in comparison to only two (9.5%) patients with-
out comorbidity, reported at least one traumat-
ic event (this difference was statistically signif-
icant). The mean GAF score in the comorbid 
group was 74.4, compared to 88.2 in the non-co-
morbid group, a difference that was highly sig-
nificant (p<0.01). The patients from the comor-
bid group also more often reported current to-
bacco smoking (Tab. 3).
To detect other possible associations of comor-
bidity with the investigated variables, the direct 
comparisons of non-comorbid group (group 1) 
with two other comorbid groups, i.e. with comor-
bid anxiety disorders (group 3) and with comor-
bid both anxiety and SUDs (group 5) were con-
ducted. Group 4 (patients with comorbid SUDs 
only) was not included in the comparisons due to 
the very limited number of subjects (n=6).
The comparison of the non-comorbid group 
with group 3 revealed significant differences in 
Substance use disorders 
(without nicotine)
18 58.1 9 21.4 <0.05 20 40.0 7 30.4 NS
Alcohol 17 54.8 5 11.9 <0.001 18 36.0 4 17.4 NS
Sedatives and hypnotics 4 12.9 6 14.3 NS 6 12.0 4 17.4 NS
Drugs 2 6.7 0 0 NS 2 4.1 0 0.0 NS
Nicotine 23 74.2 20 47.6 <0.05 36 72.0 7 30.4 <0.01
Substance use disorders 
(with nicotine)
25 80.7 24 57.1 <0.05 40 80.0 9 39.1 <0.01
Table 3. Comparison of the group of bp patients without comorbidity (group 1) with the group of bp patients with any comorbid-
ity (group 2) – categorical and continuous variables
VArIAbLE Gr 1 (N= 21) Gr 2 (N=52) p
N (%) (χ2)
Sex
 Male
 Female
6 (19.3)
15 (35.7)
25 (80.7)
27 (64.3)
NS
place of residence
 City 
 Country
18 (85.7)
3 (14.3)
40 (76.9)
12 (23.1)
NS
Education
 primary
 Vocational
 High school
 College/University
0 (0.0)
2 (33.3)
9 (23.7)
10 (37.0)
2 (3.8)
4 (7.7)
29 (55.8)
17 (32.7)
NS
Marital status (married) 13 (61.9) 34 (65.4) NS
Full or part time employment 17 (81.0) 26 (50.0) < 0.05
Disability pension 7 (33.3) 32 (61.5) < 0.05
continuation of the table on the next page
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* rapid cycling – four or more episodes per year
** Student’s t-test was performed for normally  
distributed variables
mean GAF-scores (88.2 vs. 75.0, p<0.01) and em-
ployment status, with 81% of the patients from 
the non-comorbid group being currently em-
ployed, and only 44 % from the anxiety comor-
bid group (p<0.05) (Tab. 4).
The non-comorbid group and group 5 (with 
comorbid both anxiety and SUDs) varied in the 
greatest number of variables. The patients with 
comorbid disorders from both diagnostic groups 
had significantly more lifetime suicidal ideation 
(85.7% vs. 52.4%, p<0.05) and lifetime suicide at-
tempts (42.9% vs. 14.3%, p<0.05) than did bipolar 
patients without comorbidity. They also had a 
higher mean number of psychiatric hospitaliza-
tions (6.9 vs. 4.1, p<0.05) and lower mean GAF-
bipolar subtype
 I
 II
13 (61.9)
8 (38.1)
37 (71.1)
15 (28.9)
NS
First episode
 Depressive
 (Hypo-) manic
14 (66.7)
7 (33.3)
39 (75.0)
13 (25.0)
NS
History of rapid cycling* 7 (33.3) 22 (42.3) NS
Lifetime suicidal ideation 11 (52.4) 35 (67.3) NS
Lifetime suicide attempts 3 (14.3) 14 (26.9) NS
Switch after antidepressants 9 (42.9) 29 (55.7) NS
Family history of mood 
disorders 12 (57.1) 28 (53.8) NS
SUDs in family 5 (23.8) 19 (36.5) NS
Suicide attempts in family 4 (19.1) 12 (23.1) NS
Committed suicides in family 3 (14.3) 8 (15.4) NS
Comorbid somatic conditions 9 (42.9) 20 (38.5) NS
Head traumas 1 (4.8) 10 (19.2) NS
Lifetime traumatic events 2 (9.5) 19 (36.5) < 0.05
tobacco smoking 7 (33.3) 34 (65.4) < 0.05
Intimate relationships ever 19 (90.5) 50 (96.1) NS
Children 14 (66.7) 36 (70.6) NS
MEAN (SD)
Age** 42.7 (9.8) 45.3 (11.5) NS
Onset of bp (age) 28.5 (8.7) 28.0 (9.8) NS
Age at first suicide attempt 30.3 (8.3) 31.4 (12.2) NS
Age at first hospitalization 33.2 (9.7) 33.6 (10.4) NS
No. of hospitalizations 4.1 (3.7) 6.0 (5.8) NS
Longest hospitalizations  
(months) 2.3 (1.7) 2.7 (1.8) NS
Max. ann. no. of 
hospitalizations  1.4 (0.7) 1.7 (0.9) NS
GAF 88.2 (12.0) 74.4 (15.3) < 0.01
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scores (72.2 vs. 88.2, p<0.01). Comorbid group 5 
patients more often reported having experienced 
a traumatic event (47.6% vs. 9.5%, p<0.05), more 
often had a depressive onset (95.2% vs. 66.7%, 
p<0.05), and were more often male (61.9%vs 
28.9%, p<0.05) (Tab. 5).
To assess possible relationships between the 
type of comorbid disorders and investigated var-
iables, the comorbid anxiety group and comor-
bid “mixed” group (anxiety + SUDs) were also 
compared. The “mixed” group patients were 
significantly more often men (61.9% vs. 28 %, 
p<0.05) and had more often a depressive onset 
(95.2% vs. 68%, p<0.05). The “mixed” group re-
ported more often having experienced traumat-
ic events (47.6% vs. 20%, p<0.05), had a high-
er mean number of psychiatric hospitalizations 
(6.9 vs. 5.2, p<0.05) and a tendency (p=0.052) to 
report suicidal ideation more often (85.7% vs. 
56%, p<0.05).
dISCUSSION
The comorbidity was high and reached 71.2% 
in the studied group. Similar results have also 
been reported in many clinical studies. McElroy 
et al. [2] assessed comorbidity in a group of 288 
BP I and BP II patients, using DSM-IV criteria, 
as high as 65%, with the prevalence of both anx-
iety and SUDs of 42%. Suppes et al. [3] stud-
ied a heterogeneous group of 261 BP I, BP II, BP 
Table 4. Comparison of the group of bp patients without comorbidity (group 1) with the group of bp patients with anxiety disor-
ders comorbidity (group 3).
Table 5. Comparison of the group of bp patients without comorbidity (group 1) with the group of bp patients with both anxiety 
disorders and SUDs comorbidity (group 5).
VArIAbLE Gr 1 (N = 21) Gr 3 (N = 25) p
 N (%) (χ2)
Full or part time employment 17 (81.0) 11 (44.0) < 0.05
tobacco smoking 7 (33.3) 15 (60.0) = 0.08
MEAN (SD) (U)
Max ann. no. of hospitalizations 1.4 (0.7) 1.6(0.6) = 0.07
GAF 88.2 (12.0) 75.0 (14.6) < 0.01
VArIAbLE Gr 1 (N = 21) Gr 5 (N = 21) p
 N (%) (χ2)
Sex
  Male
  Female
6 (28.6)
15 (71.4)
13 (61.9)
8 (38.1) < 0.05
First episode 
  Depressive
  (Hypo-) manic
14 (66.7)
7 (33.3)
20 (95.2)
1 (4.8) < 0.05
Lifetime suicidal ideation                  11 (52.4) 18 (85.7) < 0.05
Lifetime suicide attempts 3 (14.3) 9 (42.9) < 0.05
Lifetime traumatic events 2 (9.5) 10 (47.6) < 0.05
tobacco smoking 7 (33.3) 15 (71.4) < 0.05
MEAN (SD) (U)
No. of  hospitalizations 4.1(3.7) 6.9 (5.1) < 0.05
GAF 88.2 (12.0) 72.2 (17.3) < 0.01
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NOS and bipolar schizoaffective patients, and 
assessed DSM-IV comorbidity at 67%. The prev-
alence rate of anxiety disorders was 44% and of 
SUDs 41%. In the epidemiological NCS, where 
CIDI was also applied, all the patients with BP 
I fulfilled the diagnostic criteria for at least one 
comorbid diagnosis. The prevalence of comor-
bid anxiety disorder was similarly higher (93%) 
than SUDs (71.1%) [6, 11].
In our study, GAD was the most prevalent anx-
iety disorder (31.5%). Many other authors have 
also confirmed its frequent association with BP. 
In NCS, 42.4% of BP patients fulfilled GAD cri-
teria [12, 13].
The high prevalence rate of SP (27.4%) is some-
what surprising. The reported rates by other au-
thors are lower (10-20%) [2, 14, 15, 16]. Only Tam-
an and Ozpoyraz, in a group of 70 BP I patients 
in remission, reported a similar rate (25.7%) [17]. 
It might be possible that our result is higher due 
to patients mistakenly attributing the criterion 
of impaired professional, social or interperson-
al functioning (criterion E) that was actually the 
result of the basic disorder to the fact of experi-
encing phobic anxiety.
SAD was the third most prevalent anxiety dis-
order in the studied group (19.2%). Although clin-
ical studies assessed SAD in as broad a range as 
from 1.55% to 31.1%, it was the most prevalent 
comorbid disorder in NCS, with a rate of 47.2%. 
Our study suggests, however, the increased prev-
alence of this disorder in BP cases compared to 
the general population (3-13%) [18].
The frequent comorbidity of PD±Ago with BP 
is consistently reported across different stud-
ies. In many studies it is the most prevalent co-
morbid disorder [2, 4, 16, 19, 20]. We have as-
sessed this comorbidity to be 17.8%, which is 
quite similar to the results of Henry et al. (16%) 
[19], Simon et al. (17.3%) [21], Cosoff and Haf-
ner (15%) [14], and McElroy et al. (20%) [2] in 
clinical samples, and those of Chen and Dilsav-
er (20.8%) [22], who analyzed data from Epide-
miologic Catchment Area Study (ECA), or those 
of Angst (12.5%) in the Zurich Cohort Study [23]. 
All presented results are much higher than the 
rates reported for the general population, both 
of PD (1.5-5%) and of panic attacks not meeting 
the full criteria of PD (3-5.6%) [18]. Only Vieta et 
al. assessed the PD-BP comorbidity at 2.32%, but 
still since the results were low for all the anxie-
ty disorders (7%), PD was the most frequent co-
morbid anxiety diagnosis [4].
The comorbidity of OCD in BP has been as-
sessed in many clinical and epidemiological 
studies. Whereas in ECA it reached 21% [24], in 
the Hungarian epidemiological study [25] and in 
the Swiss study conducted by Angst [23], it was 
much lower (respectively 3.2 and 5.4%). Some 
clinical research reported high rates of comor-
bidity between BP and OCD (21.1-38.6%) [14, 17, 
20, 26], whereas another set of studies reported 
moderate or low rates (3-13.4%) [2, 16, 19, 21]. 
Our results (4.1%) do not confirm the very fre-
quently reported phenomenon of BP-OCD co-
morbidity, and are similar to those obtained by 
Henry et al. in the group of 318 hospitalized BP 
patients (3%) [19].
In our sample, alcohol use disorders were very 
common (30.1%), which is consistent with the 
results of other clinical (20-33%) [2, 5, 27] and 
epidemiological (21.4%) [23] studies. It should 
be mentioned that some studies revealed signif-
icantly higher (61.2-66.7%) [11, 26, 28] or low-
er (6.9%-15.2%) [4, 7, 29] rates, but the studies 
were quite heterogeneous in many aspects (e.g. 
base population or diagnostic tools and criteria 
employed).
In our study, sedatives and hypnotics abuse 
or dependence was similarly or less prevalent 
(13.7%) than in groups studied by other authors 
(2.5-10%), who used structuralized diagnostic 
tools [2, 5, 7, 23, 27]. On the contrary, Muesser et 
al. revealed the comorbid sedatives and hypno-
tics abuse or dependence in a group of 41 BP in-
patients to be 20% using a non-structured clini-
cal interview [26]. This may confirm the hypoth-
esis that the use of structured diagnostic tools 
may be blind to the subgroup of abusing pa-
tients in which the sedative-hypnotic use disor-
ders have clearly iatrogenic provenance.
The comorbidity of drugs abuse or depend-
ence in our study, which is lower than cited in 
the literature, is possibly due to limited access 
or the high black market price of the substance 
of abuse in Poland, especially cocaine, which is 
very often abused by BP patients.
Our research is probably one of very few stud-
ies that assessed the comorbidity of nicotine use 
disorders in BP. We assessed this comorbidity to 
be 58.9%, which is within the boundaries of that 
given by Kaplan and Sadock’s Synopsis of Psy-
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chiatry (70%) [18] and those obtained by Angst 
in his epidemiological study (46.4%) [23]. Smok-
ing can therefore be a very serious medical issue 
in this population.
We did not confirm the higher rates of co-
morbidity in bipolar women than men report-
ed by some authors [30]; moreover, we found 
comorbidity to be higher in men (80.6%) than 
in women (64.3%), but the difference was statis-
tically insignificant. We did not confirm the in-
creased prevalence of comorbid anxiety disor-
ders in women either, as did some other authors 
[30, 31], but it was not the case with SUDs. SUDs 
with or without inclusion of nicotine use disor-
ders were significantly more prevalent in bipo-
lar men than women (80.7% vs. 57.1% and 58.1% 
vs. 21.4% respectively). The most prominent dif-
ference that was highly significant (p<0.001) be-
tween sexes was in alcohol use disorder comor-
bidity. 54.8% of men and only 11.9% of women 
with BP met the abuse or dependence criteria. 
Similarly highly significant (P<0.001) differenc-
es in alcoholism were observed by Henrick et al. 
(48.4% vs. 20.3%) [32] and Frye et al. (49.1% vs. 
29.1%) [33]. Both groups of researchers noticed, 
however, that the prevalence of alcohol use dis-
orders was approximately 2.5 times higher in bi-
polar men than men from the general popula-
tion (in ECA: 23.8% [34]), and 4 to 7 times high-
er in bipolar women than women from the gen-
eral population (in ECA: 4.6%[34]). Our results, 
although confirming the higher alcohol use dis-
orders comorbidity in men, do not support the 
thesis that it is bipolar women who are more in 
danger of developing SUDs in comparison to 
women from the general population.
The next significant difference between sexes 
concerned nicotine use disorders, which were 
more prevalent in bipolar men (74.2%) than bi-
polar women (47.6%). We do not know of other 
studies that have explored this issue.
We did not find significant differences between 
bipolar subtypes in general rates of comorbidity, 
nor did we find any differences in the comorbid-
ity of the whole group of anxiety disorders and 
SUDs. The lack of statistically significant differ-
ences in comorbidity between BP subtypes was 
also reported by Simon et al [21], McElroy et al. 
[22] and Suppes et al. [3], who studied relatively 
large groups. Our results, although statistically 
insignificant, show slightly higher rates of gen-
eral and SUDs comorbidity in BP I than in BP II, 
but lower rates of comorbid anxiety disorders 
in BPI. This might indicate a possible relation-
ship of SUDs with manic episodes [35, 36], and 
of some anxiety disorders or their subtypes with 
bipolar spectrum [37, 38, 39], which have been 
reported in the literature. The only significant 
differences between BP subtypes were found in 
PD-BP comorbidity (24% vs. 4.3%, p<0.05) and 
in nicotine use disorder comorbidity (72% vs. 
30.4%, p<0.01), which were both more preva-
lent in BP I. This may indicate the existence of a 
special relationship of PD with BP I, but not BP 
II, and requires further research. Other authors 
have not confirmed this association [2, 23], al-
though in the group studied by Simon et al. [16] 
18.3% of BP I patients and 13.9% of BP II patients 
met the criteria for PD±Ago, but the difference 
was not significant.
The direct comparisons of non-comorbid BP 
cases with the “all comorbid” BP cases revealed 
that the latter were less frequently employed 
and more often took disability pension, as well 
as had lower GAF scores, which may represent 
a worse quality of remission. The “all comorbid” 
group patients experienced traumatic life events 
more often and smoked more often.
Further comparisons that were performed con-
firmed lower employment rate and GAF scores, 
as well as more frequent smoking and higher 
maximal annual number of psychiatric hospi-
talizations, in the group of “anxiety comorbid” 
patients.
The largest total number of significant dif-
ferences, also in critical clinical variables, was 
detected between the non-comorbid BP group 
and the “mixed comorbid” group. The latter had 
more frequent suicidal ideations and attempts in 
anamnesis, a higher total number of psychiatric 
hospitalizations, lower GAF scores, more trau-
matic life events, and more often smoked. The 
patients from the “mixed” comorbid group also 
more often had a depressive onset of BP.
Our findings of lower employment rates and 
more frequent disability pension uptake in co-
morbid BP patients are in congruence with the 
results of McElroy et al. [2] and Simon et al. [21], 
who reported poorer professional functioning of 
BP patients with comorbidity.
Lower GAS scores in BP patients with comor-
bidity were registered by Young et al. [40], and 
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some other groups reported poorer functioning 
or worse quality of remission in those patients 
[32].
The association of traumatic life events with 
comorbidity in BP patients detected in our study 
has not been reported so far. It should be men-
tioned that the assumed definition of a traumatic 
event was very broad and not specific. A “trau-
matic event” had been defined as an experience 
of sexual, physical or verbal abuse. The results 
should be therefore treated as explorative and 
require further research.
The association of comorbidity with suicidal-
ity has been also confirmed by many other au-
thors. The increased rates of suicidal ideation or 
attempts were reported in studies that had tak-
en into account anxiety disorders and SUDs co-
morbidity with BP only, as well as many differ-
ent classes of comorbid disorders summarized 
in one comorbid group.
Our findings that BP patients with comorbid 
both anxiety and SUDs disorder are particular-
ly suicidal are similar to those of Pini et al., who 
compared four groups of BP patients: with co-
morbid SUDs, with comorbid SUDs and other 
psychiatric disorders, with comorbid non-SUDs, 
and without comorbidity. In the logistic regres-
sion model, they detected a significant relation-
ship of comorbidity with disorders from both di-
agnostic groups (i.e. SUDs and other psychiatric 
disorders) with attempted suicide rate [31].
Our results also confirmed the relationship of 
comorbidity in BP with higher hospitalization 
rates, a fact observed by some other authors [41, 
42, 43].
To our knowledge, the association of comor-
bidity with smoking has not been reported so 
far. If this result were replicated, and the charac-
ter of this relationship further clarified, it would 
be of great clinical significance.
The main limitations of the present study are: 
1) a relatively small group of outpatients, which 
prevents undertaking a multivariate analysis 
and make the findings of preliminary rather 
than confirmatory character, 2) the lack of a con-
trol group, which disallows comparisons with a 
normal population or another psychiatrically ill 
group, 3) retrospective assessment of comorbid-
ity and investigated variables, which may influ-
ence the reliability of the analyzed data, 4) pos-
sible biases (Berkson’s bias [44], interviewer’s 
bias) that also decrease reliability and prevent 
the generalization of the results. Our study has, 
however, some noticeable strengths, which are: 
1) the relative heterogeneity of the studied group 
(only BP I and BP II patients were assessed), 2) 
the use of structured assessment instruments 
and DSM-IV criteria, which increase the relia-
bility and comparability of the results, 3) the in-
clusion of patients in remission only, which sup-
ports good compliance and possibly positively 
influences the reliability of the data.
CONCLUSIONS
Lifetime psychiatric comorbidity is a wide-
spread problem in BP. It is associated with less 
favourable clinical characteristics of BP, but the 
character of these associations and the nosolog-
ical status of comorbid cases require further re-
search. There may exist gender – and BP subtype 
– specific patterns of comorbidity in BP which 
need to be further clarified.
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